Asia
It was a very busy week for clinical trial news. Here’s a look.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
Eisai indicated it was voluntarily withdrawing the drug, but in a statement noted it disagreed with the FDA’s interpretation of the data and believes the drug’s benefits outweigh the cancer risk.
Vela Diagnostics Submitting Novel Coronavirus Diagnostic Test to FDA for Emergency Use Authorization
Vela Diagnostics has developed the ViroKeyTM SA201 COVID-19 RT-PCR Test, a new diagnostic test for the detection of the COVID-19 coronavirus. Vela Diagnostics is currently in discussions with the U.S. Food and Drug Administration for clearance of the test under the emergency use authorization.
There is a significant amount of work being done on cardiovascular diseases. Here’s a look at just some of the recent news.
The outbreak of the coronavirus, now called COVID-19, is taking some unexpected twists and turns.
The company’s efforts appear to be working, as it reported fourth-quarter results that exceeded expectations. Company shares popped 9.1% at the news.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name, COVID-19.
PRESS RELEASES